<unk>  (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia. In early 2011, it successfully completed phase IIa clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase IIb clinical trials for schizophrenia began. Avineuro Pharmaceuticals has also expressed intention to start clinical trials of<unk>  for Alzheimer's disease in 2015.
AVN-211
SHIRPA
AVN-101
ScotSTAR
Co-codaprin
MPI-CDG
ORG-2058
MOPP 